<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Warm autoimmune hemolytic anemia (AIHA) in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Warm autoimmune hemolytic anemia (AIHA) in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Warm autoimmune hemolytic anemia (AIHA) in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carlo Brugnara, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert A Brodsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert T Means, Jr, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 13, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies that react with self red blood cells (RBCs) and cause them to be destroyed. Warm AIHA, due to antibodies that are active at body temperature, is the most common type of AIHA.
        </p>
        <p>
         This topic reviews the evaluation and management of warm AIHA in adults.
        </p>
        <p>
         Separate topic reviews discuss:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AIHA in children
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">
          "Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107301.html" rel="external">
          "Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced AIHA
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cold-induced hemolytic anemias
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">
          "Paroxysmal cold hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General approach to evaluating for hemolytic anemia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1608470047">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolysis
         </strong>
         – Hemolysis refers to destruction of red blood cells (RBCs). It can occur intravascularly (within the circulation) or extravascularly (in the reticuloendothelial system, consisting mostly of splenic and hepatic macrophages). Hemolysis usually causes anemia, but the hemoglobin may be normal if there is sufficient compensation by reticulocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune hemolytic anemia (AIHA)
         </strong>
         – Autoimmune hemolysis is hemolysis caused by autoantibodies. It contrasts with alloimmune hemolysis, in which the individual produces antibodies against foreign RBC antigens (eg, those on allogeneic RBCs following a blood transfusion or on fetal RBCs during a pregnancy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Warm AIHA
         </strong>
         – Warm AIHA is due to an antibody that is active at normal body temperature. Typically the antibody is an IgG [
         <a href="#rid1">
          1
         </a>
         ]. This contrasts with hemolytic anemias in which the antibodies are most efficient in the cold (cold agglutinin disease [CAD; typically due to IgM antibodies] and paroxysmal cold hemoglobinuria [PCH; typically due to IgG antibodies]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary versus secondary warm AIHA
         </strong>
         – Primary warm AIHA (previously called idiopathic) refers to warm AIHA with no underlying condition or medication that could be responsible. Secondary warm AIHA refers to warm AIHA in the setting of an underlying condition. (See
         <a class="local">
          'Associated conditions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Warm agglutinin
         </strong>
         – Is another name for an anti-RBC antibody that is active at body temperature. These antibodies can cause agglutination (sticking together) of RBCs when treated with an antibody-binding reagent in the laboratory. However, these antibodies rarely cause agglutination of RBCs in vivo. They are IgG, which only has two valences and cannot bind more than two RBCs at a time. In contrast, cold agglutinins typically do agglutinate RBCs in vivo because they are IgM, which is pentameric and binds many RBCs simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Panagglutinin
         </strong>
         – An antibody that reacts with all reagent RBCs. Typically found with warm AIHA. Alloantibodies usually react to specific RBC antigens (eg, Kell, Kidd). Cold agglutinins often have specificity against i or I. (See
         <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">
          "Red blood cell (RBC) transfusion in individuals with serologic complexity", section on 'Panagglutination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiglobulin test (Coombs test)
         </strong>
         – A laboratory test for antibodies directed against RBCs  (
         <a class="graphic graphic_figure graphicRef100639" href="/z/d/graphic/100639.html" rel="external">
          figure 1
         </a>
         ). It is used for evaluating the cause of hemolytic anemia as well as in the blood bank for pretransfusion testing and evaluation of transfusion reactions. (See
         <a class="local">
          'Direct antiglobulin (Coombs) testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Direct
         </strong>
         – Assays antibodies and/or complement bound to the RBCs by incubating patient RBCs with anti-human globulin and anti-human C3d.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indirect
         </strong>
         – Assays antibodies in the serum by incubating patient plasma with test RBCs and anti-human globulin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3923665366">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Warm AIHA can arise spontaneously (primary [idiopathic] warm AIHA) or in the setting of a condition or medication that predisposes to the production of an autoantibody (secondary warm AIHA).
        </p>
        <p class="headingAnchor" id="H1824392163">
         <span class="h2">
          Antibody and antigen characteristics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The autoantibodies are almost always IgG, although IgA and warm-acting IgM have been reported [
         <a href="#rid1">
          1-4
         </a>
         ]. The subtype of IgG likely influences the rate of red blood cell (RBC) destruction, with IgG3 and IgG1 most able to fix complement and thus more destructive than other subtypes [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3964.html" rel="external">
          "IgG subclasses: Physical properties, genetics, and biologic functions", section on 'Complement activation'
         </a>
         .)
        </p>
        <p>
         The autoantibodies are typically polyclonal panagglutinins directed against common RBC antigens. This contrasts with alloantibodies, which typically react with RBC antigens specific to a donor's blood group. Most commonly, warm autoantibodies are directed against the Rh complex or against glycophorin antigens.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rh complex
         </strong>
         – The Rh complex consists of several proteins including Rh (which can express D, Cc, or Ee antigens), glycophorin B, and CD47. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Rh blood group system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycophorin antigens
         </strong>
         – Glycophorin antigens are heavily glycosylated proteins on which blood group antigens are located. Glycophorin A contains the M and N antigens; glycophorin B contains the S antigen. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'MNS blood group system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These antigens are typically present on RBCs in the majority of individuals, making it more challenging to find compatible blood for transfusion if needed; however, transfusion should not be withheld due to this issue. Emergency release blood can be used if needed. (See
         <a class="local">
          'Stabilization and transfusion for severe anemia'
         </a>
         below.)
        </p>
        <p>
         In one series of individuals with coronavirus disease 2019 (COVID-19) and AIHA, the antibodies appeared to react to RBCs from other individuals with COVID-19 but not with reagent RBCs, suggesting that some aspect of the infection is modifying the RBC membrane to promote antibody binding [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'COVID-19'
         </a>
         below.)
        </p>
        <p>
         Anti-RBC autoantibodies with unusual antigen specificity (eg, against Jka, auto-anti-f, auto-anti-S) have been reported [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1122895248">
         <span class="h2">
          Red cell destruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         In warm AIHA, RBCs are mostly cleared extravascularly (in reticuloendothelial macrophages). Intravascular hemolysis may be seen in severe cases if the reticuloendothelial system becomes overwhelmed or if the complement membrane attack complex is deposited on the RBC surface.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenic macrophages
         </strong>
         – Macrophages in the spleen have Fc-gamma receptors that recognize and phagocytose the IgG heavy chain and a portion of the RBC membrane, producing a spherocyte [
         <a href="#rid1">
          1
         </a>
         ]. Less commonly, the entire RBC may be phagocytosed. The slow passage of RBCs through the spleen fosters prolonged interaction between multiple IgG molecules and multiple Fc receptors in a patch of membrane of the phagocytic cell, enhancing phagocytic clearance. Spherocytes are less deformable than normal RBCs and become trapped in splenic sinusoids, further extending the time during which phagocytosis can occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenic lymphocytes
         </strong>
         – Cytotoxic T lymphocytes (CTLs) in the spleen also carry Fc receptors and can cause cell-mediated cytotoxicity of RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatic macrophages
         </strong>
         – Hepatic macrophages have receptors for complement C3 fragments and can phagocytose RBCs with complement on their surface.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1366795259">
         <span class="h2">
          Associated conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 50 to 60 percent of warm AIHA is associated with an underlying condition, with the remainder classified as primary (idiopathic) [
         <a href="#rid4">
          4,9,10
         </a>
         ]. The underlying condition generally produces some combination of immune activation, immune deficiency, or immune dysregulation.
        </p>
        <p>
         As examples [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Includes viral infections such as HIV, Epstein Barr virus (EBV), or hepatitis C virus (HCV). AIHA has been reported with hepatitis E virus [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cases of AIHA with SARS-CoV-2 (the virus that causes coronavirus disease 2019 [COVID-19]) have also been reported [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="local">
          'COVID-19'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune disorders
         </strong>
         – Includes autoimmune disorders including systemic lupus erythematosus (SLE), rheumatoid arthritis, scleroderma, or ulcerative colitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoproliferative disorders
         </strong>
         – Includes autoimmune lymphoproliferative syndrome (ALPS), chronic lymphocytic leukemia (CLL), lymphoma, and monoclonal gammopathies (multiple myeloma, monoclonal gammopathy of undetermined significance [MGUS], Waldenström macroglobulinemia). Therapy with a purine analog such as
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         can increase the risk of AIHA and can exacerbate the severity of AIHA if already present. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia", section on 'Immune-mediated'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some cases, a lymphoproliferative disorder may become apparent after the diagnosis and treatment of primary warm AIHA or warm AIHA associated with a connective tissue disorder. In a series of 107 patients with primary AIHA, 18 percent developed a lymphoproliferative disorder after a median time of approximately two years (range, 9 to 76 months) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunodeficiency
         </strong>
         – states including inherited immunodeficiencies, hematopoietic stem cell transplant (HCT), solid organ transplant, and hypogammaglobulinemia. The reported incidence of AIHA following allogeneic HCT is 4 to 6 percent [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3966.html" rel="external">
          "Immunology of the maternal-fetal interface", section on 'Maternal systemic immune responses'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         It has been suggested that in these conditions, B-cell clones that normally produce clinically silent low levels of anti-self IgM autoantibodies are altered or de-repressed to produce IgG in high and pathogenetic titer, or that control of IgG autoreactivity by autologous IgM becomes defective [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Unusual associations that deserve special mention include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Babesia
         </strong>
         – Babesiosis appears to be associated with AIHA in individuals who are asplenic. In a cohort of 86 consecutive individuals treated for babesiosis at a single institution, six developed warm AIHA [
         <a href="#rid17">
          17
         </a>
         ]. The typical time course of AIHA was two to four weeks after diagnosis, when they had exhibited a response to antimicrobial therapy and had no evidence of parasitemia on their blood smears. All six had undergone splenectomy, whereas only 12 of the remaining 80 without AIHA (15 percent) had undergone splenectomy. All cases of AIHA resolved, although most required therapy with a prolonged course of glucocorticoids. Post-splenectomy babesiosis has also been associated with Evans syndrome  (
         <a class="graphic graphic_picture graphicRef112300" href="/z/d/graphic/112300.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Evans syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spider bite
         </strong>
         – Brown recluse spider bites can rarely cause severe intravascular hemolysis and in some cases AIHA [
         <a href="#rid19">
          19
         </a>
         ]. Management includes antivenom and transfusion if needed; case reports have described plasma exchange therapy for concomitant disseminated intravascular coagulation (DIC). (See
         <a class="medical medical_review" href="/z/d/html/6485.html" rel="external">
          "Bites of recluse spiders", section on 'Life-threatening effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6485.html" rel="external">
          "Bites of recluse spiders", section on 'Acute hemolytic anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organ transplant
         </strong>
         – Solid organ transplant recipients who receive an ABO-compatible, but not identical, allograft can develop hemolysis due to passenger lymphocyte syndrome (donor lymphocytes present in the transplanted organ that react with recipient RBCs). (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Transplant recipients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7330.html" rel="external">
          "Anemia and the kidney transplant recipient", section on 'Later (&gt;3 months) posttransplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sickle cell disease
         </strong>
         – Individuals with sickle cell disease can develop a condition called bystander hemolysis, in which a delayed hemolytic transfusion reaction leads to hemolysis of self RBCs along with transfused RBCs. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Hyperhemolytic crisis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128123.html" rel="external">
          "Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Alloimmunization and hemolysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3395984546">
         <span class="h2">
          Medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications associated with drug-induced warm AIHA are summarized in the table  (
         <a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">
          table 1
         </a>
         ) and reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia", section on 'Immune-mediated'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3182382654">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – The incidence of AIHA, estimated from national registry studies, ranges from 17.0 per 100,000 (Denmark) to 2.4 per 100,000 (France) [
         <a href="#rid20">
          20,21
         </a>
         ]. A 2021 review cited an incidence of 5 to 10 per 1 million [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proportion of all AIHAs
         </strong>
         – Warm AIHA constitutes approximately 70 to 80 percent of AIHAs, with the remainder due to cold-induced hemolysis or other less common disorders [
         <a href="#rid1">
          1,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence of secondary warm AIHA
         </strong>
         – The approximate prevalence of warm AIHA in selected underlying conditions is as follows [
         <a href="#rid15">
          15,23
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic lymphocytic leukemia (CLL) – 11 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic lupus erythematosus (SLE) – 10 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Allogeneic hematopoietic stem cell transplantation – 4 to 6 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Non-Hodgkin lymphoma – 2 to 3 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prevalence of secondary AIHA is generally higher in referral centers [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is significant heterogeneity in presenting symptoms, ranging from mild to fulminant, as illustrated in several case series [
         <a href="#rid4">
          4,9,25
         </a>
         ].
        </p>
        <p>
         Findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         – Anemia-related symptoms (dyspnea on exertion, fatigue, bounding pulse or palpitations) are seen in at least three-fourths of individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Jaundice
         </strong>
         – Jaundice or dark urine are seen in approximately one-third.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenomegaly
         </strong>
         – Seen in approximately one-third. In some cases, splenomegaly is due to an underlying lymphoproliferative disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest pain
         </strong>
         – Seen in 7 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evans syndrome
         </strong>
         – Seen in 7 percent. (See
         <a class="local">
          'Evans syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The severity of symptoms depends on the hemoglobin level, its rate of decline, other comorbidities, and the person's overall level of activity or exertion. Most adults will become symptomatic when the hemoglobin declines to 8 to 9 g/dL [
         <a href="#rid26">
          26
         </a>
         ]. With severe anemia, an individual may become lethargic, confused, and/or hemodynamically unstable.
        </p>
        <p>
         The physical examination may show pallor and/or jaundice. Moderate splenomegaly may be present. Individuals with severe anemia and/or underlying cardiac disease may have signs and symptoms of cardiac decompensation (tachycardia, tachypnea, or signs of heart failure).
        </p>
        <p class="headingAnchor" id="H1798334670">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H95525343">
         <span class="h2">
          Important information from the history
         </span>
         <span class="headingEndMark">
          —
         </span>
         AIHA may be suspected in an individual with new onset anemia not due to bleeding. They may have an underlying condition associated with AIHA such as systemic lupus erythematosus (SLE) or chronic lymphocytic leukemia (CLL), or they may be otherwise well.
        </p>
        <p>
         This history can focus on:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known or suspected underlying conditions and medications associated with AIHA  (
         <a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">
          table 1
         </a>
         ). Systemic symptoms such as new-onset weight loss, night sweats, or fever may suggest development of a lymphoproliferative disorder, which is one of the most common underlying conditions. (See
         <a class="local">
          'Associated conditions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Findings that suggest an especially severe course:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemoglobinuria suggests intravascular hemolysis, which may occur in severe warm AIHA, cold agglutinin disease (CAD), paroxysmal nocturnal hemoglobinuria (PNH), or paroxysmal cold hemoglobinuria (PCH). (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">
          "Paroxysmal cold hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thromboembolic events including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction can complicate AIHA. The absolute increased risk of DVT or PE may be as high as 30 percent. Symptoms of these complications should be reviewed, both to determine if they are present and to educate the patient regarding symptoms to report to their clinician should they occur. (See
         <a class="local">
          'Thromboembolic complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe anemia (or anemia that develops rapidly) can cause lethargy, chest pain, and/or confusion. Anemia that causes these symptoms or hemodynamic compromise (or any hemoglobin &lt;6 g/dL if hemodynamically stable) is a medical emergency that requires immediate intervention with transfusions and/or other treatments, regardless of the cause. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Emergency release blood for life-threatening anemia or bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elements of the history that suggest a diagnosis other than AIHA:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transfusions
         </strong>
         – For those with a very recent transfusion (prior one to three days), an acute hemolytic transfusion reaction (AHTR) is possible, and the transfusion medicine service or blood bank should be contacted immediately to assist with the evaluation and perform antibody testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For those with a transfusion in the prior four weeks (possibly longer), a delayed hemolytic transfusion reaction (DHTR) is possible and similar discussions with transfusion medicine or the blood bank should occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Serial monitoring of the hemoglobin level and hemolysis indicators following a transfusion reaction will generally show progressive recovery. (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Evaluation and immediate management of AHTR'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Evaluation of DHTR and DSTR'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cold-induced symptoms
         </strong>
         – Cold-induced symptoms (acrocyanosis, Raynaud phenomenon) may suggest CAD. Raynaud phenomenon may also occur in connective tissue disorders. If there is suspicion for one of these conditions based on clinical features or laboratory findings, specialized testing should be performed, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4017174749">
         <span class="h2">
          Initial testing (CBC, blood smear, hemolysis labs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals being evaluated for warm AIHA will likely have already had a complete blood count (CBC) that shows anemia and/or reticulocytosis as well as other testing consistent with hemolysis, as summarized in the table  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 2
         </a>
         ) and listed below.
        </p>
        <p>
         The following testing should be obtained if not available:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBC
         </strong>
         – Anemia is usually present but may be absent if hemolysis is mild and/or reticulocytosis is brisk. A typical hemoglobin at presentation is between 7 and 10 g/dL, although hemoglobin &lt;7 g/dL is not uncommon (seen in 30 percent of individuals in one study) [
         <a href="#rid25">
          25
         </a>
         ]. The anemia is usually normocytic or macrocytic due to reticulocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serial CBCs and reticulocyte counts are often obtained to monitor severity and response to treatment. (See
         <a class="local">
          'Monitoring and prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other findings associated with known associated conditions may include an increased white blood cell (WBC) count in CLL or reduced platelet count with concomitant immune thrombocytopenia (ITP).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reticulocyte count
         </strong>
         – The reticulocyte count can be measured as an absolute count or a percentage of red blood cells (RBCs); the absolute count is preferred because it is unaffected by the hemoglobin concentration. If the absolute count is not available, the reticulocyte percentage can be corrected for the hemoglobin, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'High reticulocyte count'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The reticulocyte count increases as the bone marrow responds and begins to produce new RBCs. In one series, the mean reticulocyte percentage was 9 percent at diagnosis (mean corrected reticulocyte count, 7.4 percent; median corrected reticulocyte count, 5 percent [range, 0.1 to 45 percent]) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some cases, the reticulocyte response may be less than expected (less than twofold increase over baseline), due to one or more of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Delay in bone marrow responsiveness [
         <a href="#rid25">
          25,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Concomitant condition that decreases RBC production such as iron deficiency, hematologic malignancy, or a chemotherapy drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autoantibody directed against an antigen on RBC precursors, such as certain Rh antigens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the reticulocyte count is low in the setting of AIHA, these possibilities should be investigated, as discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Hemolysis without reticulocytosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Haptoglobin
         </strong>
         – Haptoglobin is typically low or absent/unmeasurable [
         <a href="#rid9">
          9
         </a>
         ]. In a small predictive modeling study (100 patients), a haptoglobin &lt;25 mg/dL had a sensitivity of 83 percent, specificity of 96 percent, and predictive value of 87 percent for hemolytic anemia [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactate dehydrogenase (LDH) and indirect bilirubin
         </strong>
         – LDH is typically increased. In one series, the median LDH was approximately 500 units/L, but wide variations up to 5000 units/L have been reported [
         <a href="#rid4">
          4,29
         </a>
         ]. Indirect bilirubin is in the range of 2 to 3 mg/dL (35 to 51 micromol/L) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood smear
         </strong>
         – Spherocytes or microspherocytes are often seen  (
         <a class="graphic graphic_picture graphicRef53523" href="/z/d/graphic/53523.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef50601" href="/z/d/graphic/50601.html" rel="external">
          picture 3
         </a>
         ). In some cases, spherocytes may represent a small population or may be difficult to appreciate [
         <a href="#rid9">
          9,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reticulocytes may be apparent as larger, purplish RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other findings may indicate a known associated condition. Examples include numerous small lymphocytes in CLL and reduced platelets with ITP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Also important is the absence of findings that raise the possibility of other causes of anemia, such as schistocytes, target cells, and other abnormal cell shapes. (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Worrisome findings'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Signs of intravascular hemolysis (hemoglobinemia [red serum], hemoglobinuria [red urine, positive for hemoglobin but negative for RBCs], and hemosiderinuria) are not typical of warm AIHA but may be present in severe cases.
        </p>
        <p class="headingAnchor" id="H2292854345">
         <span class="h2">
          Direct antiglobulin (Coombs) testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once hemolysis is identified, direct antiglobulin testing (DAT; Coombs) is used to distinguish immune from non-immune causes. The principles and mechanics of the tests are illustrated in the figure  (
         <a class="graphic graphic_figure graphicRef100639" href="/z/d/graphic/100639.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         In the DAT, patient RBCs are washed and reacted with antiserum or monoclonal antibodies directed against immunoglobulins, particularly IgG and a fragment of the third component of complement, C3d. The reagent antibodies will only bind and agglutinate the patient's RBCs if those RBCs already have IgG or C3d on their surface. When these tests are accurately and specifically performed, 97 to 99 percent of individuals with warm AIHA will have a positive result with anti-IgG, anti-C3d, or both, compared with less than 1 percent of the general population [
         <a href="#rid31">
          31-33
         </a>
         ]. The strength of the DAT positivity is generally correlated with the severity of hemolysis. Drug-induced AIHA may have a negative DAT. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         .)
        </p>
        <p>
         In contrast to the DAT, the indirect antiglobulin test (IAT; indirect Coombs test) is not used to evaluate warm AIHA. The IAT detects anti-RBC antibodies in the patient's serum and is most important for identifying and characterizing alloantibodies prior to transfusion.
        </p>
        <p>
         The antigen specificity of the antibody is also important. Warm AIHA autoantibodies are almost always panagglutinins reacting with all reagent RBCs. In contrast, alloantibodies virtually always have specificity for individual RBC antigens. Drug-induced hemolytic anemias generally do not show panagglutinin activity, although there are exceptions. (See
         <a class="local">
          'Antibody and antigen characteristics'
         </a>
         above.)
        </p>
        <p>
         Patterns of reactivity in different autoimmune hemolytic anemias are summarized in the table  (
         <a class="graphic graphic_table graphicRef128183" href="/z/d/graphic/128183.html" rel="external">
          table 3
         </a>
         ). A positive DAT for IgG and/or C3d in a person with hemolytic anemia who has not had a recent transfusion and does not have a cold agglutinin or Donath-Landsteiner antibody is considered confirmatory of warm AIHA. However, it is worth noting that some individuals without hemolysis will have a positive DAT; thus, this test alone (in the absence of hemolysis) is not sufficient to make the diagnosis [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Although uncommon, some individuals have combined warm-active IgG autoantibodies and cold-active IgM autoantibodies (so-called mixed autoimmune hemolytic anemia). In a series of 308 individuals, 24 (8 percent) were in this category [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Also uncommon is DAT-negative warm AIHA, which is thought to be present in &lt;5 percent of individuals with warm AIHA [
         <a href="#rid15">
          15
         </a>
         ]. The negative DAT may be due to characteristics of the autoantibodies that make them more difficult to detect or due to a reduced amount of autoantibodies on the surface of RBCs [
         <a href="#rid35">
          35,36
         </a>
         ]. For individuals suspected to have DAT-negative warm AIHA based on new-onset hemolytic anemia without evidence of another cause, the following additional testing is indicated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An extended DAT panel can be performed to identify antibodies of the IgA or IgM isotype, using specific anti-IgA or anti-IgM antisera, respectively [
         <a href="#rid2">
          2,37-42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing using more sensitive methods such as flow cytometry can sometimes identify IgG bound to RBCs [
         <a href="#rid43">
          43
         </a>
         ]. However, testing such as the "super Coombs" is rarely needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for cold-reacting antibodies (cold agglutinins or Donath-Landsteiner antibodies, indicative of CAD or PCH, respectively), if not done already  (
         <a class="graphic graphic_table graphicRef103370" href="/z/d/graphic/103370.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry for PNH using specialized methods such as fluorescent aerolysin (FLAER) and antibodies against CD59 and CD55 to detect lack of glycosylphosphatidylinositol (GPI)-anchored proteins on RBCs and WBCs [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In individuals with spherocytes on the blood smear, the possibility of hereditary spherocytosis may be considered, especially if spherocytes are abundant and/or the patient has a positive family history of hemolytic anemia. (See
         <a class="medical medical_review" href="/z/d/html/7079.html" rel="external">
          "Hereditary spherocytosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H257261843">
         <span class="h2">
          Additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing may be appropriate in selected cases, either to confirm the diagnosis, to eliminate other possible diagnoses, to identify severe disease, and/or to identify associated conditions. The need for added testing depends on the certainty of the warm AIHA diagnosis; the severity of hemolysis; and the perceived likelihood of underlying conditions that disrupt immune homeostasis, which is based on the history, CBC, and physical examination. As noted below, we have a low threshold for evaluating for underlying lymphoproliferative disorders.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirmatory testing
         </strong>
         – Additional testing with an extended DAT panel or more sensitive assays such as those described above may be reasonable in individuals for whom the diagnosis of warm AIHA is strongly suspected but DAT is negative. This is likely to be the case in &lt;5 percent of individuals with warm AIHA. (See
         <a class="local">
          'Direct antiglobulin (Coombs) testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testing for alternate diagnoses
         </strong>
         – In cases where suspicion for other causes of hemolytic anemia is high, additional testing may be indicated. An important example is oxidant hemolysis from medications such as
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , especially if findings such as blister cells or bite cells are present on the peripheral blood smear. Details of the evaluation are individualized according to the clinical history and findings on laboratory testing. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Post-diagnostic testing to determine the cause'
         </a>
         and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to test for PNH in an individual with AIHA and a negative DAT before making the diagnosis of DAT-negative warm AIHA. (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testing to identify associated
         </strong>
         <strong>
          conditions
         </strong>
         – If AIHA is diagnosed or strongly suspected, additional evaluation for underlying conditions is important.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally review the history for symptoms such as fevers, sweats, or weight loss; evaluate findings on the physical examination that may suggest an infection, a hematologic malignancy, or a rheumatologic condition; check the CBC for abnormalities of WBCs and platelets; and perform additional testing as indicated. Consultation with infectious disease, hematology, or rheumatology specialists is appropriate to assist with this testing if needed. (See
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We have a very low threshold for obtaining peripheral blood flow cytometry to identify a low-grade lymphoproliferative disorder in any adult with warm AIHA who does not have an obvious other underlying cause of hemolysis or who has any suggestive features (splenomegaly or lymphocytosis, even if mild).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some experts do even more extensive testing with additional viral serologies including HIV and hepatitis, autoantibodies such as anti-nuclear antibody (ANA) and computed tomography scans [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for thromboembolic complications
         </strong>
         – Up to 30 percent of patients with warm AIHA will have thromboembolic disease. We ask about leg swelling, chest pain, and shortness of breath, and we have a low threshold for diagnostic testing for deep vein thrombosis (DVT), cardiovascular ischemia, and/or pulmonary embolism (PE) if there are suggestive findings. As noted below, we check a D-dimer on all patients. We evaluate any patient with a positive D-dimer for DVT and any patient with dyspnea out of proportion to the degree of anemia for PE. (See
         <a class="local">
          'Thromboembolic complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3445640238">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Warm AIHA is diagnosed when an individual has antibody-mediated (DAT [Coombs]-positive) hemolytic anemia not due to another cause such as a hemolytic transfusion reaction, PNH, or CAD  (
         <a class="graphic graphic_algorithm graphicRef108335" href="/z/d/graphic/108335.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         DAT-negative warm AIHA is diagnosed when other causes of non-immune hemolysis have been eliminated, including PNH, hereditary spherocytosis, cold-active antibodies (paroxysmal cold hemoglobinuria or cold agglutinin disease), hemoglobinopathies, and thrombotic microangiopathies. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Post-diagnostic testing to determine the cause'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cold agglutinin disease (CAD)
         </strong>
         – CAD is a form of autoimmune hemolytic anemia in which IgM antibodies recognize red blood cell (RBC) antigens (typically "I" or "i") at temperatures below normal body temperature. Like warm AIHA, there is extravascular hemolysis, anemia, and a positive direct antiglobulin (Coombs) test (DAT). Unlike warm AIHA, CAD is most typical in individuals over 60 years of age, it is also associated with acrocyanosis, the DAT is typically positive for complement and negative for IgG  (
         <a class="graphic graphic_table graphicRef103370" href="/z/d/graphic/103370.html" rel="external">
          table 4
         </a>
         ), and a cold agglutinin is present with a titer ≥64 at 4°C. The peripheral blood smear in CAD shows RBC agglutination  (
         <a class="graphic graphic_picture graphicRef50522" href="/z/d/graphic/50522.html" rel="external">
          picture 4
         </a>
         ), whereas in warm AIHA it shows microspherocytes  (
         <a class="graphic graphic_picture graphicRef53523" href="/z/d/graphic/53523.html" rel="external">
          picture 2
         </a>
         ). Management also differs. (See
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced hemolytic anemia
         </strong>
         – Drug-induced hemolytic anemia can be immune or non-immune. Like warm AIHA, immune drug-induced hemolytic anemia is characterized by hemolysis and a positive DAT. Unlike warm AIHA, in drug-induced AIHA there is an implicated drug  (
         <a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">
          table 1
         </a>
         ), and the hemolysis typically abates when exposure to the drug is removed. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paroxysmal cold hemoglobinuria (PCH)
         </strong>
         – PCH is a form of autoimmune hemolytic anemia that typically presents with intravascular hemolysis, hemoglobinemia, and darkly colored urine (hemoglobinuria), beginning a few minutes to several hours after exposure to cold along with the presence of an IgG antibody that reacts with the red cell at reduced temperature but not at 37°C and causes hemolysis on rewarming (ie, a positive Donath-Landsteiner antibody test). The DAT is positive for the presence of complement, but not IgG, during the acute hemolytic episode. (See
         <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">
          "Paroxysmal cold hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paroxysmal nocturnal hemoglobinuria (PNH)
         </strong>
         – PNH is a form of hemolytic anemia caused by an acquired hematopoietic stem cell defect that leads to complement-mediated hemolysis; there is no autoantibody involved. Like warm AIHA, it often affects older adults and is associated with markers of increased hemolysis. Unlike warm AIHA, the DAT is negative for IgG, and PNH-specific flow cytometry shows absence of glycosylphosphatidylinositol (GPI)-anchored proteins. (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hereditary
         </strong>
         <strong>
          spherocytosis (HS)
         </strong>
         – HS is a
         <strong>
          non-immune
         </strong>
         form of hemolytic anemia due to inherited pathogenic variants in genes that encode cytoskeletal proteins. However, HS may be confused with AIHA due to the abundance of spherocytes and the lack of symptoms due to the chronicity of the disorder. Like warm AIHA, individuals with HS have hemolysis and anemia, with spherocytes on the blood smear. Unlike warm AIHA, individuals with HS generally have lifelong anemia and may have a positive family history of anemia, and laboratory testing is consistent with a non-immune mechanism of hemolysis (negative DAT, positive assay for eosin-5’-maleimide [EMA] binding to RBCs). (See
         <a class="medical medical_review" href="/z/d/html/7079.html" rel="external">
          "Hereditary spherocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3199272176">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management depends on the severity of the anemia. An approach is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef127838" href="/z/d/graphic/127838.html" rel="external">
          algorithm 2
         </a>
         ). As illustrated in the algorithm and discussed below, individuals with severe anemia may require transfusion and hemodynamic support. Once the patient is stabilized, the approach to reducing hemolysis and halting antibody production is similar for most patients. (See
         <a class="local">
          'Stabilization and transfusion for severe anemia'
         </a>
         below.)
        </p>
        <p>
         The autoantibodies have a half-life of two to three weeks; thus, even if therapy immediately halts production of the autoantibody, hemolysis may continue for two to three weeks.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         is generally used for those with persistent hemolysis, and venous thromboembolism (VTE) prophylaxis is used for those who are hospitalized. (See
         <a class="local">
          'Folic acid'
         </a>
         below and
         <a class="local">
          'Thromboembolic complications'
         </a>
         below.)
        </p>
        <p>
         Management of individuals who have a recurrence of autoimmune hemolysis after recovery are treated similarly to those with a first episode of AIHA, with the exception that treatments that were effective during the initial episode may be prioritized for treating subsequent episodes.
        </p>
        <p class="headingAnchor" id="H278855849">
         <span class="h2">
          Stabilization and transfusion for severe anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a patient first presents, the blood bank or transfusion service may require some time to perform pretransfusion testing and identify appropriate units for transfusion. However, severe anemia (hemoglobin &lt;6 g/dL) and/or hemodynamic compromise from a rapid decline in hemoglobin is a medical emergency requiring immediate stabilization and usually transfusion. Delay in transfusion could be fatal. These patients should be transfused with emergency release blood pending the full blood bank evaluation. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Emergency release blood for life-threatening anemia or bleeding'
         </a>
         .)
        </p>
        <p>
         Other emergency treatment may also be required for severely anemic or hemodynamically compromised patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stabilize the patient with intravenous access and hydration. Provide ventilatory and circulatory support as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contact the blood bank or transfusion medicine liaison
         <strong>
          immediately
         </strong>
         and alert them of the need for transfusion in an individual with AIHA [
         <a href="#rid45">
          45,46
         </a>
         ]. Important history for the blood bank or transfusion medicine service includes prior pregnancies and prior transfusions, which may have led to alloantibody production. If the patient is coming from an outside hospital, it is important to give them the name of the hospital since that hospital may have already started the work-up.
        </p>
        <p>
        </p>
        <p>
         Once compatible blood has been identified:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The transfusion threshold appropriate to that patient should be used. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If information about alloantibodies is known (due to previous transfusions or pregnancy), blood with these antigens should be avoided, as alloimmune hemolysis is much more likely to cause a significant transfusion reaction than hemolysis caused by autoantibodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients requiring transfusion should receive type-specific blood, even if crossmatch-compatible blood cannot be identified by the blood bank (which will be the case for many patients) [
         <a href="#rid1">
          1
         </a>
         ]. For individuals who are at risk of previous sensitization to RBC alloantigens due to prior transfusions or pregnancy, blood can be infused slowly (over three to four hours) with close monitoring; using a slower rate during the first 30 to 60 minutes is most important.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If transfusion is not required urgently and there is sufficient time to perform extended phenotype matching, matching for Rh, Kell, Kidd, and S/s antigens is advised [
         <a href="#rid1">
          1
         </a>
         ]. Some guidelines also include matching for Duffy. Genotyping may be helpful if available [
         <a href="#rid42">
          42
         </a>
         ]. The amount of time involved in extended phenotyping (or genotyping) varies, and close communication with the blood bank is advised to share information about the degree of clinical urgency and the amount of testing that can reasonably be performed. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Clinically significant (common)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">
          "Red blood cell (RBC) transfusion in individuals with serologic complexity", section on 'Autoantibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In one of the largest case series of AIHA (mostly warm type), 115 of 308 patients (37 percent) received transfusions [
         <a href="#rid4">
          4
         </a>
         ]. Historical experience indicates that most patients will tolerate even serologically incompatible blood [
         <a href="#rid47">
          47,48
         </a>
         ]. One report, for example, described 53 patients with decompensated AIHA who received blood transfusions in which none had transfusion-related alloimmunization or a definite increase in hemolysis [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         If transfusion-dependent hemolysis continues, we may add intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG). (See
         <a class="local">
          'IVIG'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2388439101">
         <span class="h2">
          Treatment of the underlying disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately one-half of individuals with warm AIHA have an associated/underlying disorder that causes immune dysregulation. (See
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
         Treatment of the underlying disorder is appropriate, although this may not always lead to resolution of hemolysis, or it may work more slowly than needed [
         <a href="#rid1">
          1,42
         </a>
         ]. Treatment is especially important for infections that may be clinically serious in their own right.
        </p>
        <p>
         For some underlying disorders such as chronic lymphocytic leukemia (CLL), it may be reasonable to treat the AIHA without initiating CLL-specific therapy, especially if the AIHA rather than CLL is the predominant clinical feature [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Details of management for underlying disorders are presented in separate topic reviews. Examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug discontinuation. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus (SLE). (See
         <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">
          "Overview of the management and prognosis of systemic lupus erythematosus in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune lymphoproliferative syndrome (ALPS). (See
         <a class="medical medical_review" href="/z/d/html/16614.html" rel="external">
          "Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL. (See
         <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">
          "Overview of the treatment of chronic lymphocytic leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin disease. (See
         <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">
          "Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-Hodgkin lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">
          "Initial treatment of limited stage diffuse large B cell lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">
          "Initial treatment of advanced stage diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Decisions about the role of splenectomy are highly dependent on the underlying disorder, with efficacy in some disorders such as splenic marginal zone lymphoma and worsening in others such as ALPS. (See
         <a class="local">
          'Splenectomy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H848067488">
         <span class="h2">
          Glucocorticoids with or without rituximab as first-line agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the patient's hemodynamic status has been addressed, most experts use glucocorticoids plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as the initial treatment of warm AIHA, especially for symptomatic patients [
         <a href="#rid1">
          1,10
         </a>
         ]. This applies to individuals with primary or secondary AIHA.
        </p>
        <p>
         If a patient who starts on single agent glucocorticoids has no response by two weeks, we start
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and frequently add
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil. The glucocorticoids should be tapered over several weeks to avoid late toxicities. (See
         <a class="local">
          'Rituximab (alone or added to glucocorticoids)'
         </a>
         below and
         <a class="local">
          'Other immunosuppressive and cytotoxic agents'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial dose
         </strong>
         – Most experts use an initial dose of 1 to 2 mg/kg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         orally per day or a dose of 60 to 100 mg daily [
         <a href="#rid50">
          50
         </a>
         ]. If parenteral administration is preferred, an equivalent dose of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (0.8 to 1.6 mg/kg intravenously per day) can be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This is generally continued until the hemoglobin is &gt;10 mg/dL, which occurs in most patients within two to three weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most experts add
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         to initial glucocorticoids, especially for individuals with severe disease. Two randomized trials (discussed below) have demonstrated greater efficacy with glucocorticoids plus rituximab compared with glucocorticoids alone. (See
         <a class="local">
          'Rituximab (alone or added to glucocorticoids)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Taper
         </strong>
         – Once the hemoglobin level has stabilized and markers of hemolysis are normal or clearly improving (typically over two to three weeks), a taper can be initiated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The general principle of tapering glucocorticoids in AIHA is to use a gradual taper over two to three months (some experts suggest longer) [
         <a href="#rid1">
          1,51
         </a>
         ]. However, we may taper more rapidly for individuals at high risk for complications (eg, diabetes). There is no high-quality evidence to support one specific tapering protocol over another.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, we do the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the patient is responsive to initial steroid therapy (hemoglobin of 10 g/dL or more within three weeks) reduce
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose by 10 mg per week until the dose reaches 20 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Once the dose is 20 mg daily, decrease the dose no faster than 5 mg per week (often we decrease by 5 mg every other week).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Relapse is an indication for second-line therapy with or without a boost in the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose. (See
         <a class="local">
          'Treatment for persistent disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We also consider lack of a response within three weeks to indicate steroid-unresponsive disease. We taper glucocorticoids in these individuals by 10 mg per week and initiate a second-line therapy to avoid toxicities of long-term glucocorticoid use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         During the taper, we monitor the complete blood count (CBC), reticulocyte count, and lactate dehydrogenase (LDH; more comprehensive hemolysis panel in some individuals). The frequency depends on the severity of anemia. In outpatients who continue to require regular transfusions, we obtain this testing one to two times per week. If the patient is transfusion-independent and undergoing a taper, once weekly testing is reasonable. Once the hemoglobin level is stable, the monitoring interval is extended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The likelihood of an initial response to glucocorticoids alone ranges from approximately 70 to 90 percent, based on case series and our experience [
         <a href="#rid9">
          9,52
         </a>
         ]. However, as many as one-half of individuals who have a response will experience a relapse within the first year [
         <a href="#rid50">
          50
         </a>
         ]. As noted below, randomized trials have demonstrated improved response rates when
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is added to glucocorticoids, without significant increases in adverse events. (See
         <a class="local">
          'Rituximab (alone or added to glucocorticoids)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Glucocorticoids may be less effective in certain populations such as individuals who develop AIHA following hematopoietic stem cell transplant, although this is very rare [
         <a href="#rid15">
          15,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addition of
         </strong>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         <strong>
          and other agents
         </strong>
         – As noted above, we typically use glucocorticoids plus rituximab as initial therapy. For individuals who did not receive rituximab as initial therapy and who do not have a response to glucocorticoids in the first two to three weeks, rituximab and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil can be added and the glucocorticoid taper initiated. (See
         <a class="local">
          'Rituximab (alone or added to glucocorticoids)'
         </a>
         below and
         <a class="local">
          'Other immunosuppressive and cytotoxic agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Glucocorticoids are generally well-tolerated over the short term but have numerous adverse effects when given for prolonged periods, including weight gain, diabetes, hypertension and cardiovascular disease, neuropsychiatric changes, osteoporosis and osteoporotic fractures, immunosuppression, and cataracts  (
         <a class="graphic graphic_table graphicRef65998" href="/z/d/graphic/65998.html" rel="external">
          table 5
         </a>
         ). These effects are thought by some to be lower when glucocorticoids are given at very low doses or on an every-other-day schedule, but there is unlikely to be a dose at which side effects are eliminated. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Patients who are on glucocorticoids for more than three months should be treated with calcium (intake of 1000 to 1200 mg daily) and vitamin D (intake of 600 to 800 international units daily), through diet and/or supplements. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
         We use prophylaxis for pneumocystis infection in individuals receiving long-term glucocorticoids plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , but not those receiving long-term glucocorticoids alone. Supporting evidence and details of administration are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H206221805">
         <span class="h2">
          Rituximab (alone or added to glucocorticoids)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         may be used as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As initial therapy in combination with glucocorticoids (our usual practice).
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Added to glucocorticoids if the hemoglobin does not improve with glucocorticoids alone.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As a single agent for initial therapy.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As a single agent for refractory disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The optimal dose, schedule, and duration of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is unknown. Many experts use 375 mg per square meter of body surface area intravenously (375 mg/m
         <sup>
          2
         </sup>
         ) weekly for four weeks, based on the schedule used in hematologic malignancies. Other doses and schedules may also be reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
         – Two randomized trials and a prospective non-randomized study have shown better response rates for
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         plus glucocorticoids than for glucocorticoids alone:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A trial from 2013 randomly assigned 64 adults with newly diagnosed warm AIHA to receive
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (1.5 mg/kg daily for two weeks followed by a taper) with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (375 mg/m
         <sup>
          2
         </sup>
         weekly for four weeks) [
         <a href="#rid29">
          29
         </a>
         ]. Compared with prednisolone monotherapy, combined therapy was associated with a better response rate at 12 months (36 versus 75 percent), with responses continuing to occur over the first six months, even after therapy had been completed. The benefit persisted for at least 36 months, with remission rates of 45 versus 70 percent. Relapse-free survival was also better in the combined therapy group (hazard ratio [HR] 0.33, 95% CI 0.12-0.88). Adverse events were similar in both groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A trial from 2017 randomly assigned 32 adults with warm AIHA to receive
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (1 mg/kg daily for two weeks followed by a taper) with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (two infusions of fixed dose 1000 mg two weeks apart) [
         <a href="#rid54">
          54
         </a>
         ]. Results were remarkably similar to the 2013 trial, with response rates at 12 months of 31 versus 75 percent, and at 24 months of 19 versus 63 percent. Adverse effects were lower in the rituximab group (fewer severe infections, likely due to chance). There were six deaths in the monotherapy group and no deaths with combination therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A prospective single arm study from 2012 treated 18 adults with warm AIHA using a short course of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and low-dose
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (100 mg fixed dose weekly for four weeks) and noted responses in all 18 that lasted for at least 36 months [
         <a href="#rid55">
          55,56
         </a>
         ]. Therapy was well tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         can cause infusion reactions and long-term immunosuppression. (See
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinicians should be aware of Boxed Warnings in the
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         prescribing information regarding infusion-related reactions, reactivation of hepatitis B infection, severe mucocutaneous reactions, as well as progressive multifocal leukoencephalopathy, any one of which may be fatal. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms of action
         </strong>
         – The mechanism by which
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         induces long-term responses is incompletely understood. It is thought to eliminate B cells via apoptosis, antibody-dependent cytotoxicity, and complement-mediated cytotoxicity [
         <a href="#rid57">
          57
         </a>
         ]. Plasma cells responsible for long-term antibody production do not express CD20 and are not eliminated by rituximab.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2868624254">
         <span class="h2">
          Folic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic hemolysis can lead to folate deficiency due to increased folate requirements for compensatory red blood cell (RBC) production.
        </p>
        <p>
         Administration of
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         (1 mg per day orally) is reasonable as long as hemolysis persists. This may not be necessary given routine folate supplementation of grains and other foods in most countries, but it is unlikely to be harmful. (See
         <a class="medical medical_review" href="/z/d/html/7153.html" rel="external">
          "Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Increased requirements'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2787457049">
         <span class="h2">
          IVIG
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) has limited efficacy as a single agent in AIHA, but it is often helpful as an adjunct to other therapies. In patients who are improving but still transfusion dependent two weeks after starting
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , we sometimes use IVIG (500 mg/kg daily for four days) to improve RBC survival and decrease the need for blood transfusions.
        </p>
        <p>
         Case reports have described use in individuals with very severe disease (doses in the range of 1 gram/kg daily for five days), with efficacy in small series of 30 to 40 percent [
         <a href="#rid58">
          58-61
         </a>
         ].
        </p>
        <p>
         Details of administration and adverse effects are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p>
         As noted above, the autoantibodies have a half-life of two to three weeks (see
         <a class="local">
          'Initial management'
         </a>
         above).
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         may help during this time by blocking macrophage Fc receptors and preventing RBC destruction in the spleen and liver.
        </p>
        <p class="headingAnchor" id="H181638118">
         <span class="h2">
          VTE prophylaxis and D-dimer testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals with brisk hemolysis (eg, severe enough to require hospital admission or to cause a significant decline in hemoglobin level), venous thromboembolism (VTE) prophylaxis should be used, as individuals with hemolysis are at increased risk for thromboembolic complications. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
         VTE prophylaxis may be used in other selected cases, such as in outpatients, especially during episodes of active or severe hemolysis, due to this increased risk.
        </p>
        <p>
         We also check a D-dimer in all new cases and perform bilateral lower extremity compression ultrasonography with Doppler in all individuals with an elevated D-dimer. (See
         <a class="local">
          'Thromboembolic complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2555493456">
         <span class="h1">
          TREATMENT FOR PERSISTENT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is common for patients to require additional treatment beyond glucocorticoids and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (approximately one-half of patients in two of the larger series) [
         <a href="#rid4">
          4,9
         </a>
         ]. This generally applies to those with a hemoglobin &lt;10 g/dL despite therapy and/or inability to taper
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to ≤10 mg daily to maintain a higher hemoglobin level.
        </p>
        <p>
         If glucocorticoids were used alone (without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) for initial therapy, we add rituximab. The major treatment options for persistent disease that does not respond to glucocorticoids and/or rituximab include a variety of other immunosuppressive and cytotoxic agents and splenectomy.
        </p>
        <p>
         Small case series have shown good responses with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         for persistent/refractory disease and for Evans syndrome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Responses in refractory disease as high as 77 to 92 percent have been reported, with a significant portion of individuals having persistent response for over a year [
         <a href="#rid62">
          62-68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Responses have been seen in some Evans syndrome case reports but not others [
         <a href="#rid69">
          69-74
         </a>
         ]. (See
         <a class="local">
          'Evans syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         These approaches have not been compared in randomized trials. We typically try at least one or two other immunosuppressive agents before splenectomy. (See
         <a class="local">
          'Other immunosuppressive and cytotoxic agents'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1622182654">
         <span class="h2">
          Other immunosuppressive and cytotoxic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various other immunosuppressive and cytotoxic agents have been reported to be effective in AIHA and can be used for individuals who do not have a good response to glucocorticoids and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         .
        </p>
        <p>
         None of these have been compared with each other in a randomized trial, and the choice among them may be individualized. We often use
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) starting at a dose of 500 mg every 12 hours and escalating the dose every 2 weeks up to 1000 mg every 12 hours if necessary. Our preference for MMF is based on our clinical experience and familiarity with this agent rather than on high-quality clinical studies.
        </p>
        <p>
         Children and young adults with coexisting autoimmune lymphoproliferative syndrome (ALPS) often have a response to
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         . Individuals with severe intravascular hemolysis are often treated with intravenous
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . We generally defer splenectomy until we have tried at least one or two other immunosuppressive agents.
        </p>
        <p>
         Individuals who do not have a response to one agent may have success with another [
         <a href="#rid75">
          75
         </a>
         ]. Responses may take several weeks to occur. The decision regarding when to switch from one agent to another (ie, deciding that an agent is ineffective) is also individualized, as responses may occur over different time frames. Generally, it is reasonable to switch if there is no response within three to four weeks (or if an agent is not well-tolerated). These therapies are stopped when a stable remission is documented.
        </p>
        <p>
         In a series of 54 patients with severe refractory AIHA from 2019, the two most commonly used agents were
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (79 percent response rate) and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (59 percent response rate) [
         <a href="#rid76">
          76
         </a>
         ]. Other small series have reported similar or even better response rates, but these are likely subject to reporting bias, and actual response rates may be lower [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclophosphamide
         </strong>
         –
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         is the most rapidly acting therapy and may be used for severe anemia due to refractory AIHA. For mild anemia due to refractory AIHA, we use one of the therapies mentioned below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When using
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , we often give a single dose of 600 to 750 mg per square meter intravenously (600 to 750 mg/m
         <sup>
          2
         </sup>
         ) to an inpatient with severe anemia who requires more than two units of RBCs per week despite glucocorticoids or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . This dose is based on personal experience; high quality studies to guide dosing are lacking. High-dose cyclophosphamide (eg, 50 mg per kg daily for four days, based on ideal body weight) has also been used [
         <a href="#rid77">
          77
         </a>
         ]. We generally do not use this approach unless the 600 to 750 mg/m
         <sup>
          2
         </sup>
         dose has been tried twice and is ineffective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         may be more effective than
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , it has numerous side effects including hair loss, gonadal toxicity, bone marrow suppression, bladder irritation with hematuria, and leukemogenesis. Bladder irritation can be minimized by giving the medication as a single dose in the morning, increasing urinary output during the day, and voiding before retiring to bed at night, or by intravenous pulse therapy. (See
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         <strong>
          mofetil (MMF)
         </strong>
         – MMF often takes weeks to months before a response occurs. Thus, we often use MMF for individuals with more stable hemolysis who can be managed in the outpatient setting. A small series of individuals treated with MMF reported many responses, including one individual with Evans syndrome [
         <a href="#rid78">
          78
         </a>
         ]. Another series that included four patients with AIHA reported responses in all four [
         <a href="#rid79">
          79
         </a>
         ]. A starting dose is 500 to 1000 mg orally per day in two divided doses, increasing to 1000 to 2000 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Azathioprine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         has been reported to result in responses, and toxicity may be less than with prolonged courses of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid71">
          71,80,81
         </a>
         ]. It is given in an initial oral dose of 100 to 150 mg orally per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Danazol
         </strong>
         – Case reports have described successful treatment with
         <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">
          danazol
         </a>
         [
         <a href="#rid75">
          75,82-84
         </a>
         ]. Dosing is started at 200 mg orally per day, increased to 600 to 800 mg per day, and reduced to 200 mg per day following response. One series of 16 individuals, including three with Evans syndrome, reported responses in 100 percent [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclosporin A
         </strong>
         – A series of 44 patients with AIHA and/or Evans syndrome reported responses to cyclosporin A in 89 percent [
         <a href="#rid86">
          86
         </a>
         ]. Smaller series have reported similar response rates [
         <a href="#rid87">
          87,88
         </a>
         ]. A starting dose is 5 to 10 mg/kg orally per day in two divided doses, with subsequent dose adjustment depending on hematologic response and renal function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fostamatinib
         </strong>
         – A trial that randomly assigned 90 individuals with refractory warm AIHA to receive
         <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">
          fostamatinib
         </a>
         or placebo found responses in 36 percent with fostamatinib and 27 percent with placebo [
         <a href="#rid89">
          89
         </a>
         ]. Post-hoc analysis that removed individuals treated with glucocorticoids showed a more dramatic difference in responses (33 percent with fostamatinib versus 14 percent with placebo). Non-life-threatening adverse events were common (diarrhea, hypertension, fatigue).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sirolimus
         </strong>
         – Children and young adults with coexisting ALPS often have a response to
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/16614.html" rel="external">
          "Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis", section on 'Autoimmune manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plasma exchange
         </strong>
         – Case reports have described use of plasma exchange in severe refractory AIHA, but in many cases, this was used in combination with immunosuppression [
         <a href="#rid90">
          90
         </a>
         ]. Plasma exchange for AIHA is considered a category III indication by the American Society for Apheresis (ASFA); category III indicates disorders for which the optimum role of apheresis therapy is not established. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'ASFA therapeutic categories'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other agents
         </strong>
         – Case reports have described use of these agents, but these therapies are unproven for warm AIHA, and we do not use them for warm AIHA in our practice:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          Alemtuzumab
         </a>
         , alone or in combination with low-dose
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid91">
          91-93
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vinca alkaloids (
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         ).
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
         [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          Daratumumab
         </a>
         [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          Eculizumab
         </a>
         [
         <a href="#rid97">
          97-99
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          Venetoclax
         </a>
         (in individuals with chronic lymphocytic leukemia [CLL]) [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H170229461">
         <span class="h2">
          Splenectomy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Splenectomy may be used if glucocorticoids and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         are ineffective, although its efficacy has never been compared with other approaches in randomized trials. Splenectomy and medical therapies listed above differ significantly in their risks and burdens, making shared decision-making especially important in the decision between them.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients should have the opportunity to understand the permanence of splenectomy, the likely efficacy, and the possible adverse effects. Some experts reserve splenectomy for individuals who have not had a good response to glucocorticoids and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (or who cannot tolerate these therapies), whereas others may prefer splenectomy to rituximab.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals are especially likely to benefit from splenectomy if they have splenic marginal zone lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">
          "Splenic marginal zone lymphoma", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of splenectomy in individuals with AIHA is similar to glucocorticoids. In 32 individuals from the GIMEMA cohort treated with splenectomy, the response rate was 75 percent [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – Splenectomy is not used in individuals if they have:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autoimmune lymphoproliferative syndrome (ALPS). (See
         <a class="medical medical_review" href="/z/d/html/16614.html" rel="external">
          "Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cold-active antibodies. (See
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">
          "Paroxysmal cold hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The rationale for avoiding splenectomy and other contraindications is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Conditions in which splenectomy is generally contraindicated'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical planning
         </strong>
         – Preoperative and postoperative concerns are similar to those for individuals with immune thrombocytopenia (ITP).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preoperative vaccinations should be provided against pneumococci, meningococci, and haemophilus, preferably at least two to three weeks before the procedure. (See
         <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">
          "Prevention of infection in patients with impaired splenic function"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Postoperative thromboprophylaxis is especially important as surgery, splenectomy, and AIHA all independently increase venous thromboembolism (VTE) risk. (See
         <a class="local">
          'Thromboembolic complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients should be educated about post-splenectomy immunosuppression and the need to address fever or other infectious symptoms promptly. (See
         <a class="medical medical_review" href="/z/d/html/1404.html" rel="external">
          "Clinical features, evaluation, and management of fever in patients with impaired splenic function"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These and other considerations such the role of laparoscopic versus open procedures are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6678.html" rel="external">
          "Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'Splenectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism
         </strong>
         – The mechanism by which splenectomy reduces hemolysis may include removal of a substantial portion of reticuloendothelial macrophages, and in some cases, removal of the lymphocytes or plasma cells that produce the autoantibodies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2114398821">
         <span class="h1">
          MONITORING AND PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most adults with AIHA have an initial response to therapy within two to three weeks. However, waxing and waning disease is common, and many individuals live with chronic disease [
         <a href="#rid1">
          1
         </a>
         ]. Patients should be educated about the possibility of relapses and to seek medical attention for recurrent symptoms or other concerns.
        </p>
        <p>
         A reasonable approach to monitoring during and after recovery is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals undergoing a glucocorticoid taper, we generally check the complete blood count (CBC) every two to four weeks, although this is highly variable depending on the patient's circumstances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals receiving chronic immunosuppressive therapy, we individualize the monitoring interval depending on the hemoglobin level (eg, more frequently for those with hemoglobin of 8 to 9 g/dL than for someone with a hemoglobin of 11 to 12 g/dL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who have had a complete response (return of their hemoglobin to baseline and no evidence of hemolysis), we generally check the CBC every three to four months during the first year and then yearly (or less frequently) unless new signs or symptoms occur.
        </p>
        <p>
        </p>
        <p>
         Relapses are treated similarly to the first episode of hemolysis, incorporating information about which agents were most effective for that individual. Individuals who did not receive
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         for the initial episode might benefit from receiving it if they have one or more relapses. (See
         <a class="local">
          'Initial management'
         </a>
         above.)
        </p>
        <p>
         Prognosis depends on the underlying condition and other factors. In the GIMEMA cohort of 308 individuals with AIHA followed for a median of approximately three years, 63 had died, 11 (3.6 percent of the entire cohort) due to their disease [
         <a href="#rid4">
          4
         </a>
         ]. Causes of death included infection, myocardial infarction, pulmonary embolism, and multi-organ failure. Evans syndrome was associated with a higher mortality (hazard ratio [HR] 6.8, 95% CI 1.99-23.63). Other series have reported survival of approximately 90 percent at three years [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H646013953">
         <span class="h1">
          THROMBOEMBOLIC COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AIHA is associated with a significantly increased risk of venous thromboembolism (VTE), which is further increased following splenectomy and with certain associated conditions.
        </p>
        <p>
         In one study, for example, of nine patients with warm AIHA who underwent splenectomy, four developed postoperative portal vein thrombosis and a fifth developed pulmonary embolism (PE) [
         <a href="#rid9">
          9
         </a>
         ]. This high rate of VTE factors into our preference for
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         over splenectomy in most cases.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We check D-dimer on
         <strong>
          all
         </strong>
         patients, and if positive, we perform bilateral lower extremity compression ultrasound to evaluate for deep vein thrombosis (DVT).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals with dyspnea out of proportion to the degree of anemia, we perform chest computed tomography to evaluate for PE.
        </p>
        <p>
        </p>
        <p>
         Other implications include the need to adhere to thromboprophylaxis during hospitalizations and other high-risk settings (eg, pregnancy), to have a low threshold for evaluating symptoms of VTE, and to avoid other prothrombotic stimuli when possible (eg, estrogen-containing contraceptives). (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
         For individuals who develop a VTE, we generally consider them high-risk for recurrence, and we often treat them with indefinite anticoagulation. If they are in a stable remission (eg, hemoglobin &gt;10 g/dL and lactate dehydrogenase [LDH] &lt;1.5 times the upper limit of normal for the laboratory) and are receiving no therapy or minimal therapy (eg, less than 10 mg daily of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ), we often discontinue anticoagulation as long as there are no other major VTE risk factors. There are no data comparing different anticoagulants in this setting, and AIHA does not influence the choice of anticoagulant in individuals with VTE associated with AIHA.
        </p>
        <p class="headingAnchor" id="H3320052294">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2739190324">
         <span class="h2">
          COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coronavirus disease 2019 (COVID-19) has been associated with AIHA, although the prevalence in different patient groups has not been well-established [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         In a series of 103 consecutive individuals who were admitted to the hospital with COVID-19 and had a sample sent to the laboratory for ABO and Rh typing or pre-transfusion testing, nearly one-half (46 percent) had a positive direct antiglobulin (Coombs) test (DAT), most of which were positive for IgG alone (without complement) [
         <a href="#rid7">
          7
         </a>
         ]. The DAT-positive individuals were more likely to be anemic (median hemoglobin, 9.8, versus 12.2 in DAT-negative patients) and to require transfusions, with a trend towards increased bilirubin and lactate dehydrogenase (LDH) that was not statistically significant, suggesting an association between the autoantibodies and clinically significant anemia. The mechanism is unknown but appeared to involve autoantibodies directed against RBCs that are in some way modified by the infection rather than directly bound by virus.
        </p>
        <p>
         We would not intervene for a positive DAT without clear evidence of hemolysis. Membrane-bound IgG can complicate pre-transfusion testing, although this should not delay transfusion in individuals with life-threatening anemia. (See
         <a class="local">
          'Stabilization and transfusion for severe anemia'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1094439418">
         <span class="h2">
          Drug-induced
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3465671855">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Warm AIHA may be exacerbated during pregnancy, and in rare instances, the maternal autoantibody may cross the placenta and affect the fetus or newborn [
         <a href="#rid102">
          102-104
         </a>
         ].
        </p>
        <p>
         In some cases, the newborn may only show a positive direct antiglobulin (Coombs) test, while some may develop severe anemia and require treatment for alloantibody-induced hemolytic anemia. (See
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy", section on 'Warm autoimmune hemolytic anemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2064604267">
         <span class="h2">
          Evans syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evans syndrome refers to the co-occurrence of two or more immune cytopenias, most often AIHA and immune thrombocytopenia (ITP) [
         <a href="#rid105">
          105
         </a>
         ]. Less commonly, some patients will also have autoimmune neutropenia (15 percent in one series) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Evans syndrome is considered more difficult to treat (less responsive to standard therapies, with more frequent relapses and higher mortality) than isolated warm AIHA. In a series of 68 patients with Evans syndrome, short-term responses were seen in over 80 percent, but only 22 (32 percent) were in remission off treatment at a median follow-up of 4.8 years, and 16 (24 percent) had died [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         We generally use glucocorticoids,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil in combination, and we often add intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) if the platelet count is &lt;20,000/microL, although supporting data are lacking.
        </p>
        <p>
         In addition to the therapies described above, case reports have described responses to hematopoietic stem cell transplantation and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid106">
          106-108
         </a>
         ]. In the series of 68 patients, responses were most likely with glucocorticoids,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and splenectomy [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids with or without rituximab as first-line agents'
         </a>
         above and
         <a class="local">
          'Rituximab (alone or added to glucocorticoids)'
         </a>
         above and
         <a class="local">
          'Splenectomy'
         </a>
         above and
         <a class="local">
          'Other immunosuppressive and cytotoxic agents'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1040324531">
         <span class="h2">
          Resource-limited settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of AIHA in communities with limited access to resources is an important consideration given the costs of extensive resources discussed above. Not surprisingly, there are a paucity of publications on this issue. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A report from South India showed reasonably good results using oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         as initial therapy (1.5 mg/kg daily for three weeks, followed by a gradual taper), with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         as a second-line therapy if glucocorticoids were ineffective [
         <a href="#rid109">
          109
         </a>
         ]. Responses were seen in 26 of 29 (90 percent) of the glucocorticoid-treated patients and 11 of 14 (79 percent) of the azathioprine-treated patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single referral center in Mexico City used glucocorticoids as first-line therapy with splenectomy as second-line therapy if glucocorticoids were ineffective [
         <a href="#rid110">
          110
         </a>
         ]. Responses were seen in 75 of 89 (84 percent) of the glucocorticoid-treated patients and in 34 of 36 (94 percent) of the patients who underwent splenectomy. Due to financial constraints,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         could only be considered as third-line therapy in only 2 of 89 patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H288088480">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">
          "Society guideline links: Anemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H109734965">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83062.html" rel="external">
          "Patient education: Autoimmune hemolytic anemia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Warm autoimmune hemolytic anemia (AIHA) is caused by autoantibodies that react with self red blood cells (RBCs) at body temperature. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Warm AIHA can arise spontaneously (primary) or associated with an autoimmune, infectious, lymphoproliferative, or immunodeficiency syndrome or medication (secondary). Approximately 50 to 60 percent of cases are secondary. Hemolysis is mostly extravascular. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – Warm AIHA affects approximately 10 per million and accounts for 70 to 80 percent of AIHA. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation
         </strong>
         – Presenting symptoms related to anemia range from mild to fulminant. Mild splenomegaly may be present. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The history focuses on underlying conditions and medications  (
         <a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">
          table 1
         </a>
         ) and possible alternate diagnoses (cold-induced symptoms, transfusion history). Laboratory evaluation includes complete blood count (CBC), reticulocyte count, hemolysis testing  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 2
         </a>
         ), and blood smear review. Direct antiglobulin (Coombs) testing distinguishes immune from nonimmune hemolysis  (
         <a class="graphic graphic_table graphicRef128183" href="/z/d/graphic/128183.html" rel="external">
          table 3
         </a>
         ). Warm AIHA is DAT-positive hemolytic anemia not due to another cause  (
         <a class="graphic graphic_algorithm graphicRef108335" href="/z/d/graphic/108335.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential
         </strong>
         – The differential diagnosis includes drug-induced hemolysis, cold agglutinin disease (CAD), paroxysmal cold hemoglobinuria (PCH), paroxysmal nocturnal hemoglobinuria (PNH), and hereditary spherocytosis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transfusions
         </strong>
         – Severe anemia (hemoglobin &lt;7 g/dL) and hemodynamic compromise are medical emergencies. Contact the blood bank or transfusion medicine liaison immediately and alert them of the need for transfusion in an individual with AIHA  (
         <a class="graphic graphic_algorithm graphicRef127838" href="/z/d/graphic/127838.html" rel="external">
          algorithm 2
         </a>
         ). Emergency release blood may be used if needed. In less urgent situations, extended phenotype matching is advised to identify the most compatible blood. (See
         <a class="local">
          'Stabilization and transfusion for severe anemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Underlying disorder
         </strong>
         – Treatment of the underlying condition is appropriate but may not always halt hemolysis rapidly  (
         <a class="graphic graphic_algorithm graphicRef127838" href="/z/d/graphic/127838.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Treatment of the underlying disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunosuppression
         </strong>
         – For symptomatic patients, we suggest a glucocorticoid (
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 to 2 mg/kg daily for two to three weeks followed by a very slow taper) plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (four weekly treatments) rather than a glucocorticoid alone  (
         <a class="graphic graphic_algorithm graphicRef127838" href="/z/d/graphic/127838.html" rel="external">
          algorithm 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). A glucocorticoid alone is reasonable if hemolysis is mild and/or rituximab would create an unacceptable burden toxicity. (See
         <a class="local">
          'Glucocorticoids with or without rituximab as first-line agents'
         </a>
         above and
         <a class="local">
          'Rituximab (alone or added to glucocorticoids)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Second-line treatments
         </strong>
         – For individuals lacking an initial response, we add
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if not given previously. Therapy for those who lack a response to glucocorticoids and rituximab is individualized; we often use
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil. Children and young adults with coexisting autoimmune lymphoproliferative syndrome often have a response to
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         . Individuals with severe intravascular hemolysis are often treated with intravenous
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . We generally defer splenectomy until one or two other immunosuppressive agents have been tried. (See
         <a class="local">
          'Treatment for persistent disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         – We suggest daily folic acid (1 mg) as long as hemolysis continues (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Folic acid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Monitoring includes CBC, reticulocyte count, and lactate dehydrogenase (LDH). The interval depends on severity and disease course. Initial responses are common, but many individuals require retreatment periodically. (See
         <a class="local">
          'Monitoring and prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Up to 30 percent of patients have thromboembolic complications. We check a D-dimer in all patients and evaluate for deep vein thrombosis (DVT) if the D-dimer is high. We evaluate for pulmonary embolism in any patient with dyspnea out of proportion to the degree of anemia. (See
         <a class="local">
          'Thromboembolic complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1560396357">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
        </p>
        <p>
         The UpToDate editorial staff acknowledges Wendell F Rosse, MD, who contributed to earlier versions of this topic review.
        </p>
        <p>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med 2019; 381:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reusser P, Osterwalder B, Burri H, Speck B. Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up. Acta Haematol 1987; 77:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokol RJ, Booker DJ, Stamps R, et al. IgA red cell autoantibodies and autoimmune hemolysis. Transfusion 1997; 37:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014; 124:2930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelfriet CP, Borne AE, Beckers D, Van Loghem JJ. Autoimmune haemolytic anaemia: serological and immunochemical characteristics of the autoantibodies; mechanisms of cell destruction. Ser Haematol 1974; 7:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schur PH. IgG subclasses--a review. Ann Allergy 1987; 58:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berzuini A, Bianco C, Paccapelo C, et al. Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood 2020; 136:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs JW, Binns TC, Abels E, et al. Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity. Am J Clin Pathol 2023; 160:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol 2014; 89:E150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med 2021; 385:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leaf RK, O'Brien KL, Leaf DE, Drews RE. Autoimmune hemolytic anemia in a young man with acute hepatitis E infection. Am J Hematol 2017; 92:E77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol 2020; 190:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez C, Kim J, Pandey A, et al. Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br J Haematol 2020; 190:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res 2001; 7:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcellini W, Fattizzo B, Zaninoni A. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. J Blood Med 2019; 10:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahl D, Lacroix-Desmazes S, Heudes D, et al. Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. Blood 2000; 95:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woolley AE, Montgomery MW, Savage WJ, et al. Post-Babesiosis Warm Autoimmune Hemolytic Anemia. N Engl J Med 2017; 376:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shatzel JJ, Donohoe K, Chu NQ, et al. Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis. Transfusion 2015; 55:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichner ER. Spider bite hemolytic anemia: positive Coombs' test, erythrophagocytosis, and leukoerythroblastic smear. Am J Clin Pathol 1984; 81:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen DL, Möller S, Andersen K, et al. Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016. Clin Epidemiol 2020; 12:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maquet J, Lafaurie M, Walter O, et al. Epidemiology of autoimmune hemolytic anemia: A nationwide population-based study in France. Am J Hematol 2021; 96:E291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcellini W. Immune Hemolysis: Diagnosis and Treatment Recommendations. Semin Hematol 2015; 52:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006; 65:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tranekær S, Hansen DL, Frederiksen H. Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood 1987; 69:820.
          </a>
         </li>
         <li class="breakAll">
          Jones J. Transfusion in oligemia. In: Blood Transfusion in Clinical Medicine, 8th ed, Mollison PL, Engelfriet CP, Contreras M (Eds), Blackwell, Oxford 1987. p.41.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980; 244:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013; 163:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantripragada K, Quesenberry PJ. Doublet spherocytes. Blood 2014; 124:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaplin H Jr. Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias. Prog Hematol 1973; 8:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler CA, Calhoun L, Blackall DP. Warm reactive autoantibodies: clinical and serologic correlations. Am J Clin Pathol 2004; 122:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sachs UJ, Röder L, Santoso S, Bein G. Does a negative direct antiglobulin test exclude warm autoimmune haemolytic anaemia? A prospective study of 504 cases. Br J Haematol 2006; 132:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meulenbroek EM, Wouters D, Zeerleder SS. Lyse or not to lyse: Clinical significance of red blood cell autoantibodies. Blood Rev 2015; 29:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Podberezin M, Levina A, Romanova L, et al. Quantitation of red cell-bound immunoglobulins and complement in lymphoma patients. Immunohematology 2000; 16:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bencomo AA, Diaz M, Alfonso Y, et al. Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. Immunohematology 2003; 19:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garratty G, Arndt P, Domen R, et al. Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed against determinants on or associated with glycophorin A. Vox Sang 1997; 72:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janvier D, Sellami F, Missud F, et al. Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1). Transfusion 2002; 42:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardill B, Mengis C, Tschopp M, Wuillemin WA. Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman. Eur J Haematol 2003; 70:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion 2009; 49:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartolmäs T, Salama A. A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies. Transfusion 2010; 50:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2018; 2018:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thedsawad A, Taka O, Wanachiwanawin W. Significances of red cell bound immunoglobulin G as detected by flow cytometry in patients with Coombs-negative immune hemolysis. Transfus Med 2016; 26:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petz LD. A physician's guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 2004; 124:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ness PM. How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations? Transfusion 2006; 46:1859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol 1988; 10:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salama A, Berghöfer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340:1515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuh AH, Parry-Jones N, Appleby N, et al. Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. Br J Haematol 2018; 182:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood 2017; 129:2971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014; 99:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zupańska B, Sylwestrowicz T, Pawelski S. The results of prolonged treatment of autoimmune haemolytic anaemia. Haematologia (Budap) 1981; 14:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosoba S, Jaye DL, Cohen C, et al. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion 2015; 55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol 2017; 92:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119:3691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol 2013; 91:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993; 44:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macintyre EA, Linch DC, Macey MG, Newland AC. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol 1985; 60:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majer RV, Hyde RD. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin Lab Haematol 1988; 10:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 2009; 266:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010; 89:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Sun J. [Lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia]. Zhonghua Xue Ye Xue Za Zhi 2014; 35:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006; 81:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16:2092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bussone G, Ribeiro E, Dechartres A, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol 2009; 84:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maung SW, Leahy M, O'Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol 2013; 163:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 2004; 77:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009; 114:3167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michel M. [Warm autoimmune hemolytic anemias and Evans syndrome in adults]. Rev Med Interne 2008; 29:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008; 50:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park CY, Chung CH. A patient with mixed type Evans syndrome: efficacy of rituximab treatment. J Korean Med Sci 2006; 21:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AC, Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. J Rheumatol 1991; 18:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hantaweepant C, Pairattanakorn P, Karaketklang K, et al. Efficacy and safety of second-line treatment in Thai patients with primary warm-type autoimmune hemolytic anemia. Hematology 2019; 24:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002; 100:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005; 75:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002; 117:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirofsky B. Immune haemolytic disease: the autoimmune haemolytic anaemias. Clin Haematol 1975; 4:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worlledge SM, Brain MC, Cooper AC, et al. Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia. Proc R Soc Med 1968; 61:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993; 83:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn YS, Harrington WJ, Mylvaganam R, et al. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985; 102:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinohara K, Okafuji K, Ayame H, Ueda N. [Idiopathic autoimmune hemolytic anemia successfully treated with danazol]. Rinsho Ketsueki 1990; 31:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cervera H, Jara LJ, Pizarro S, et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995; 22:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu H, Shao Z, Jing L. [The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome]. Zhonghua Xue Ye Xue Za Zhi 2001; 22:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 1996; 93:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsudo M, Moriguchi T. [Effective cyclosporine therapy to resistant-Evans syndrome]. Rinsho Ketsueki 1996; 37:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ, Piatek C, Röth A, et al. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). Am J Hematol 2024; 99:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva VA, Seder RH, Weintraub LR. Synchronization of plasma exchange and cyclophosphamide in severe and refractory autoimmune hemolytic anemia. J Clin Apher 1994; 9:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 2010; 116:4783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fadlallah J, Michel M, Crickx E, et al. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol 2019; 187:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratnasingam S, Walker PA, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 2016; 1:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv 2018; 2:2550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma K, Caplan S. Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Rep Hematol 2016; 2016:9181698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neave L, Wilson AJ, Lissack M, Scully M. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab. BMJ Case Rep 2018; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rovira J, Cid J, Gutiérrez-García G, et al. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev 2013; 27:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galindo-Navarro P, Delgado-García A, Rodríguez-Gil MA, Puerta-Puerta JM. Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain. Haematologica 2023; 108:2261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yılmaz F, Kiper D, Koç M, et al. Clinical Features and Treatment Outcomes of Warm Autoimmune Hemolytic Anemia: A Retrospective Analysis of 60 Turkish Patients. Indian J Hematol Blood Transfus 2019; 35:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokol RJ, Hewitt S, Stamps BK. Erythrocyte autoantibodies, autoimmune haemolysis and pregnancy. Vox Sang 1982; 43:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawe JE. Successful exchange transfusion of an infant for AIHA developing late in mother's pregnancy. Transfusion 1982; 22:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williamson TD, Liles LH, Blackall DP. A maternal warm-reactive autoantibody presenting as a positive direct antiglobulin test in a neonate. Immunohematology 1997; 13:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fattizzo B, Michel M, Giannotta JA, et al. Evans syndrome in adults: an observational multicenter study. Blood Adv 2021; 5:5468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2006; 132:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol 1997; 19:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyama Y, Papadopoulos EB, Miranda M, et al. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001; 28:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhu R, Bhaskaran R, Shenoy V, et al. Clinical characteristics and treatment outcomes of primary autoimmune hemolytic anemia: a single center study from South India. Blood Res 2016; 51:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso HC, Manuel AV, Amir CG, et al. Warm autoimmune hemolytic anemia: experience from a single referral center in Mexico City. Blood Res 2017; 52:44.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7078 Version 58.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31412178" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Warm Autoimmune Hemolytic Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3107324" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9051092" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : IgA red cell autoantibodies and autoimmune hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25232059" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4215136" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Autoimmune haemolytic anaemia: serological and immunochemical characteristics of the autoantibodies; mechanisms of cell destruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3544971" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : IgG subclasses--a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32559762" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37598315" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24847759" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34614331" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Autoimmune Hemolytic Anemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28230259" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Autoimmune hemolytic anemia in a young man with acute hepatitis E infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32374906" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Autoimmune haemolytic anaemia associated with COVID-19 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32369626" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11309323" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31496855" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10607720" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28273010" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Post-Babesiosis Warm Autoimmune Hemolytic Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25354478" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6720633" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Spider bite hemolytic anemia: positive Coombs' test, erythrophagocytosis, and leukoerythroblastic smear.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32547241" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33930203" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Epidemiology of autoimmune hemolytic anemia: A nationwide population-based study in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26404442" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Immune Hemolysis: Diagnosis and Treatment Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079164" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33802848" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3814817" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3814817" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7411826" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7365971" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The predictive value of serum haptoglobin in hemolytic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23981017" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25121167" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Doublet spherocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4545113" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15491963" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Warm reactive autoantibodies: clinical and serologic correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445844" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Does a negative direct antiglobulin test exclude warm autoimmune haemolytic anaemia? A prospective study of 504 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26006097" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lyse or not to lyse: Clinical significance of red blood cell autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15373606" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Quantitation of red cell-bound immunoglobulins and complement in lymphoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15373694" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9088083" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed against determinants on or associated with glycophorin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12473132" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12631260" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18980619" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20003048" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30504336" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26914629" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Significances of red cell bound immunoglobulin G as detected by flow cytometry in patients with Coombs-negative immune hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10989647" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15009058" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A physician's guide to transfusion in autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17076838" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3180694" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Patients with red cell autoantibodies: selection of blood for transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1361607" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Red blood cell transfusion in warm-type autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30009455" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28360039" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : How I treat autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25271314" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Treatment of autoimmune hemolytic anemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6807782" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The results of prolonged treatment of autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27696475" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22267606" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24033754" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15564720" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The biology of CD20 and its potential as a target for mAb therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8237993" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4005186" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2432727" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3250787" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19549092" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20526716" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24666491" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : [Lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16823816" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12357362" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19123460" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23909468" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14601692" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15495242" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19638626" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980462" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : [Warm autoimmune hemolytic anemias and Evans syndrome in adults].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17570702" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179698" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A patient with mixed type Evans syndrome: efficacy of rituximab treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2023224" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31581907" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Efficacy and safety of second-line treatment in Thai patients with primary warm-type autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091370" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15946312" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12028047" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1102181" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Immune haemolytic disease: the autoimmune haemolytic anaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4177973" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8457484" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Danazol in autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3970469" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Danazol therapy for autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2329690" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : [Idiopathic autoimmune hemolytic anemia successfully treated with danazol].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8991983" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11855146" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : [The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639426" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8960663" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : [Effective cyclosporine therapy to resistant-Evans syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37929318" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7798158" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Synchronization of plasma exchange and cyclophosphamide in severe and refractory autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11564082" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14962245" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Monoclonal antibodies in the treatment of autoimmune cytopenias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20841509" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31155716" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296693" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30291113" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27092282" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30567234" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23562007" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36861400" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31388268" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Clinical Features and Treatment Outcomes of Warm Autoimmune Hemolytic Anemia: A Retrospective Analysis of 60 Turkish Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6814064" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Erythrocyte autoantibodies, autoimmune haemolysis and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7064209" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Successful exchange transfusion of an infant for AIHA developing late in mother's pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15387790" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A maternal warm-reactive autoantibody presenting as a positive direct antiglobulin test in a neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34592758" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Evans syndrome in adults: an observational multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16398647" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Management of Evans syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329465" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Evans syndrome: results of a national survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11781654" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Allogeneic stem cell transplantation for Evans syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27382552" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Clinical characteristics and treatment outcomes of primary autoimmune hemolytic anemia: a single center study from South India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28401101" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Warm autoimmune hemolytic anemia: experience from a single referral center in Mexico City.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
